Eli Lilly shared additional safety and tolerability details for retatrutide, its next-generation obesity medicine, as new data emerged from a late-stage program disclosed at major scientific meetings and published in The Lancet. The updates included specific counts for cardiac and serious cardiovascular events observed with the drug compared with placebo.